Chief Business Officer
CurrentActivSignal's MPAD platform (Multiplex Paired-antibody Amplified Detection assay) measures activity along multiple signaling pathways in one reaction. More than 20 signaling pathways can be monitored simultaneously in a single well by measuring 70 target proteins for modifications, cleavage and expression. The company is currently working on an NSF Phase 2 SBIR grant, applying the MPAD assay to early detection of pancreatic and other cancers. Read more at activsignal.com, and please let us know if you have ideas for contacts or collaborators in this effort.